AML in older adults (older than 60 years): long-term survival for patients with unfavorable cytogenetics. Patients received induction and consolidation therapy on trial and were randomized to receive either TAD-HAM or HAM-HAM with results that were superimposable. Reprinted from Büchner et al⁶²  with permission.